MANDALA', Mario

MANDALA', Mario  

DIPARTIMENTO DI MEDICINA E CHIRURGIA  

Mostra records
Risultati 1 - 20 di 250 (tempo di esecuzione: 0.035 secondi).
Titolo Data di pubblicazione Autore(i) File
40. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH 2018 Fuchs, Cs; Doi, T; Jang, Rw; Muro, K; Satoh, T; Machado, M; Sun, W; Jalal, Si; Shah, Ma; Metges, Jp; Garrido, M; Golan, T; Mandala', M; Wainberg, Za; Catenacci, Dv; Ohtsu, A; Shitara, K; Geva, R; Bleeker, J; Ko, Ah; Ku, G; Philip, P; Enzinger, Pc; Bang, Yj; Levitan, D; Wang, J; Rosales, M; Dalal, Rp; Yoon, Hh.
A case of severe pharyngeal-cervical-brachial syndrome induced by nivolumab and responding to infliximab therapy 2020 Indini, A; Sessa, M; Merelli, B; Foresti, C; Mandala', M
A case of sudden brain metastases progression after temporary targeted therapy discontinuation: when to regret a drug holiday 2021 Indini, Alice; Rijavec, Erika; Mandala', Mario; Castiglioni, Simona; Beltramo, Giancarlo; Grossi, Francesco
A prospective study on survival in cancer patients with and without venous thromboembolism. 2014 Agnelli, Giancarlo; Verso, Melina; Mandalà, M; Gallus, S; Cimminiello, C; Apolone, G; Di Minno, G; Maiello, E; Prandoni, P; Santoro, A; Crino', Lucio; Labianca, R.
Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1 2001 Lissoni, P; Malugani, F; Bonfanti, A; Bucovec, R; Secondino, S; Brivio, F; Ferrari-Bravo, A; Ferrante, R; Vigoré, L; Rovelli, F; Mandala', M; Viviani, S; Fumagalli, L; Gardani, Gs.
Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin 2000 Lissoni, P; Mandala', M; Brivio, F.
Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial 2010 Mandala', M; Barni, S; Prins, M; Labianca, R; Tondini, C; Russo, L; Milesi, A; Cremonesi, M; Zaccanelli, M; Regonesi, C; Moro, C; Falanga, A.
Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling 2016 Wicki, A; Mandala', M; Massi, D; Taverna, D; Tang, H; Hemmings, Ba; Xue, G
Acral lentiginous melanoma histotype predicts outcome in clinical stage I-II melanoma patients: an International multicenter study 2022 Mandala', M.; Rutkowski, P.; Galli, F.; Patuzzo, R.; De Giorgi, V.; Rulli, E.; Gianatti, A.; Valeri, B.; Merelli, B.; Szumera-Cieckiewicz, A.; Massi, D.; Maurichi, A.; Teterycz, P.; Santinami, M.
Acute dyspnea due to right phrenic palsy during infusional chemotherapy 2004 Mandala', M; Ciano, C; Ghilardi, M; Cremonesi, M; Cazzaniga, M; Barni, S.
Acute endocrine effects of interleukin-12 in cancer patients 1997 Lissoni, P; Rovelli, F; Rivolta, Mr; Frigerio, C; Mandala', M; Barni, S; Ardizzoia, A; Malugani, F; Tancini, G.
Acute vulvar vestibulitis occurring during chemotherapy with cryptophycin analogue LY355703 2000 De Pas, Tm; Mandala', M; Curigliano, G; Peccatori, F.
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma 2017 Long, Gv; Hauschild, A; Santinami, M; Atkinson, V; Mandala', M; Chiarion-Sileni, V; Larkin, J; Nyakas, M; Dutriaux, C; Haydon, A; Robert, C; Mortier, L; Schachter, J; Schadendorf, D; Lesimple, T; Plummer, R; Ji, R; Zhang, P; Mookerjee, B; Legos, J; Kefford, R; Dummer, R; Kirkwood, Jm
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 triaL 2020 Dummer, R; Brase, Jc; Garrett, J; Campbell, Cd; Gasal, E; Squires, M; Gusenleitner, D; Santinami, M; Atkinson, V; Mandala', M; Chiarion-Sileni, V; Flaherty, K; Larkin, J; Robert, C; Kefford, R; Kirkwood, Jm; Hauschild, A; Schadendorf, D; Long, Gv
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival 2021 Mandala, Mario; Larkin, James; Ascierto, Paolo Antonio; Del Vecchio, Michele; Gogas, Helen; Cowey, C Lance; Arance, Ana; Dalle, Stéphane; Schenker, Michael; Grob, Jean-Jacques; Chiarion-Sileni, Vanna; Marquez, Ivan; Butler, Marcus O; Di Giacomo, Anna Maria; Lutzky, Jose; De La Cruz-Merino, Luis; Atkinson, Victoria; Arenberger, Petr; Hill, Andrew; Fecher, Leslie; Millward, Michael; Khushalani, Nikhil I; de Pril, Veerle; Lobo, Maurice; Weber, Jeffrey
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria 2022 Larkin, J.; Weber, J.; Del Vecchio, M.; Gogas, H.; Arance, A. M.; Dalle, S.; Cowey, C. L.; Schenker, M.; Grob, J. -J.; Chiarion-Sileni, V.; Marquez-Rodas, I.; Butler, M. O.; Di Giacomo, A. M.; Middleton, M. R.; De la Cruz-Merino, L.; Arenberger, P.; Atkinson, V.; Hill, A.; Fecher, L. A.; Millward, M.; Khushalani, N. I.; Queirolo, P.; Long, G. V.; Lobo, M.; Askelson, M.; Ascierto, P. A.; Mandala', M.
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma 2017 Weber, J; Mandala', M; Del Vecchio, M; Gogas, Hj; Arance, Am; Cowey, Cl; Dalle, S; Schenker, M; Chiarion-Sileni, V; Marquez-Rodas, I; Grob, Jj; Butler, Mo; Middleton, Mr; Maio, M; Atkinson, V; Queirolo, P; Gonzalez, R; Kudchadkar, Rr; Smylie, M; Meyer, N; Mortier, L; Atkins, Mb; Long, Gv; Bhatia, S; Lebbé, C; Rutkowski, P; Yokota, K; Yamazaki, N; Kim, Tm; de Pril, V; Sabater, J; Qureshi, A; Larkin, J; Ascierto, Pa; CheckMate 238, Collaborators.
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238 2023 Larkin, J.; Del Vecchio, M.; Mandala', M.; Gogas, H.; Fernandez, A. M. A.; Dalle, S.; Cowey, C. L.; Schenker, M.; Grob, J. -J.; Chiarion-Sileni, V.; Marquez-Rodas, I.; Butler, M. O.; Di Giacomo, A. M.; Middleton, M. R.; Lutzky, J.; de la Cruz-Merino, L.; Arenberger, P.; Atkinson, V.; Hill, A. G.; Fecher, L. A.; Millward, M.; Nathan, P. D.; Khushalani, N. I.; Queirolo, P.; Ritchings, C.; Lobo, M.; Askelson, M.; Tang, H.; Dolfi, S.; Ascierto, P. A.; Weber, J.
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial 2020 Ascierto, Pa; Del Vecchio, M; Mandala', M; Gogas, H; Arance, Am; Dalle, S; Cowey, Cl; Schenker, M; Grob, Jj; Chiarion-Sileni, V; Márquez-Rodas, I; Butler, Mo; Maio, M; Middleton, Mr; de la Cruz-Merino, L; Arenberger, P; Atkinson, V; Hill, A; Fecher, La; Millward, M; Khushalani, Ni; Queirolo, P; Lobo, M; de Pril, V; Loffredo, J; Larkin, J; Weber, J
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma 2018 Eggermont, Amm; Blank, Cu; Mandala', M; Long, Gv; Atkinson, V; Dalle, S; Haydon, A; Lichinitser, M; Khattak, A; Carlino, Ms; Sandhu, S; Larkin, J; Puig, S; Ascierto, Pa; Rutkowski, P; Schadendorf, D; Koornstra, R; Hernandez-Aya, L; Maio, M; van den Eertwegh, Ajm; Grob, Jj; Gutzmer, R; Jamal, R; Lorigan, P; Ibrahim, N; Marreaud, S; van Akkooi, Acj; Suciu, S; Robert, C